Generation Bio Co. (NASDAQ:GBIO) Given Average Recommendation of "Hold" by Brokerages

Generation Bio Co. (NASDAQ:GBIO - Get Free Report) has received a consensus rating of "Hold" from the six brokerages that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $8.00.

A number of research firms have recently weighed in on GBIO. Needham & Company LLC cut their price target on shares of Generation Bio from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, March 7th. Wedbush reissued an "outperform" rating and set a $5.00 target price on shares of Generation Bio in a research report on Thursday, March 7th.

Institutional Trading of Generation Bio

Hedge funds have recently modified their holdings of the company. Osaic Holdings Inc. acquired a new position in Generation Bio in the second quarter worth about $26,000. Quantbot Technologies LP grew its position in Generation Bio by 2,566.7% in the first quarter. Quantbot Technologies LP now owns 8,000 shares of the company's stock valued at $58,000 after acquiring an additional 7,700 shares during the period. UBS Group AG raised its stake in Generation Bio by 63.1% during the second quarter. UBS Group AG now owns 10,077 shares of the company's stock worth $66,000 after acquiring an additional 3,900 shares in the last quarter. Prelude Capital Management LLC bought a new position in shares of Generation Bio during the first quarter valued at $74,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Generation Bio in the 2nd quarter valued at $56,000. Institutional investors own 95.22% of the company's stock.

Generation Bio Stock Performance

Shares of GBIO stock traded up $0.22 during trading on Monday, hitting $4.29. 468,101 shares of the company were exchanged, compared to its average volume of 283,883. The business's 50-day simple moving average is $2.55 and its 200 day simple moving average is $2.21. Generation Bio has a twelve month low of $0.86 and a twelve month high of $6.98. The firm has a market capitalization of $285.20 million, a price-to-earnings ratio of -2.19 and a beta of 2.78.

Generation Bio (NASDAQ:GBIO - Get Free Report) last posted its quarterly earnings results on Wednesday, March 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.12). The firm had revenue of $2.88 million for the quarter, compared to analyst estimates of $3.05 million. On average, equities analysts forecast that Generation Bio will post -1.41 earnings per share for the current fiscal year.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.